SPI in descent! What does this mean for your investments?

Transparenz: Redaktionell erstellt und geprüft.
Veröffentlicht am

Current developments on the Swiss Performance Index (SPI) on April 17, 2025: market analysis, winners and losers.

Aktuelle Entwicklungen zum Swiss Performance Index (SPI) am 17.04.2025: Marktanalyse, Gewinner und Verlierer.
Current developments on the Swiss Performance Index (SPI) on April 17, 2025: market analysis, winners and losers.

SPI in descent! What does this mean for your investments?

The Swiss Performance Index (SPI) recorded a decline of 0.31 percent to 15,584.62 points on Thursday, April 17, 2025, as finance.net reported. At the start of trading, the SPI was at 15,612.84 points, a decrease of 0.125 percent compared to the previous day. The daily high was registered at 15,673.70 points and the daily low at 15,540.35 points. However, since the beginning of the week, the SPI has recorded an increase of 1.51 percent.

The total value of the assets contained in the SPI amounts to 2.087 trillion euros. Compared to the past few months, the SPI has experienced significant fluctuations: a month ago the index was 17,274.75 points, three months ago it was 15,983.37 points and a year ago it was 14,897.33 points. Since the beginning of 2025, the SPI has gained 0.426 percent, while the current annual high is 17,386.61 points and the annual low is 14,361.69 points.

Current winners and losers in the SPI

The following stocks recorded the highest gains in current trading activities: SHL Telemedicine (+5.00% to CHF 2.00), Curatis (+4.50% to CHF 10.45), SoftwareONE (+3.69% to CHF 5.48), PolyPeptide (+3.47% to CHF 16.12) and Barry Callebaut (+3.10% to 764.50 CHF). On the other hand, some stocks suffered significant losses: Adval Tech (-9.84% to CHF 55.00), Molecular Partners (-3.66% to CHF 3.16), Santhera Pharmaceuticals (-3.54% to CHF 14.16), Luzerner Kantonalbank (-3.52% to CHF 68.50) and VAT (-3.32% to 270.70 CHF).

The most traded stock in the SPI is UBS stock with 2,012,134 shares traded. Nestlé has the highest market value in the SPI at 239.868 billion euros, while Relief Therapeutics shares have the lowest price-earnings ratio (P/E) in the SPI at 3.00. In addition, the BB Biotech share is expected to offer the highest dividend yield in the SPI at 10.20 percent.

A review of the SPI's performance shows that it has achieved an average return of 11.1 percent per year since its launch in 1988 fuw.ch notes. The index increased in 23 of 32 reporting periods (72%). The best years for the SPI were 2005, 1997 and 1993, with significant fluctuations throughout the year.